Soluble CD30: A biomarker for evaluating the clinical risk versus benefit of IFNβ1A treatment in multiple sclerosis patients

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 1, 2010, Pages 213-226

  Contasta, I ^a   Totaro, R ^b   Berghella, A M ^a   Pellegrini, P ^a   Del Beato, T ^a   Carolei, A ^b   Adorno, D ^a  

^a CNR Istituto Per I Trapianti d'Organo e l'Immunocitologia   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

CD30; IFN 1a therapy; Multiple sclerosis; Neuroimmunology; Risk benefit biomarkers; Th cytokine data driven modelling approaches

Indexed keywords

BETA1A INTERFERON; GLYCOPROTEIN GP 130; INTERLEUKIN 10; INTERLEUKIN 12P70; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HOMEOSTASIS; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL;

EID: 77951754396     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300119     Document Type: Article

References (35)

1. Muta H, Boise LH, Fang L, Podack ER. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol 2000; 165:5105-5111
2. Schwertassek U, Balmer Y, Gutscher M, Weingarten L, Preuss M, Engelhard J, Winkler M, Dick TP. Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin 1. EMBO J 2007; 26:3086-3097 (Pubitemid 47057486)
3. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2001; 30:421-455
4. Hargreaves PG, Al-Shamkhani A. A Soluble CD30 blocks transmembrane signaling by CD30. Eur J Immunol 2002; 32:163-173
5. PRISMS Prevention of Relapses and Disability by Interferon β 1a Subcutaneously in Multiple Sclerosis, Study Group. Randomised double blind placebo controlled study of interferon β 1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-1504
6. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-127
7. Berger T, Rubner N, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139-145 (Pubitemid 36818783)
8. Giovannoni G, Lai M, Kidd D, Thorpe JW, Miller DH, Thompson AJ, Keir G, Feldmann M, Thompson EJ. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 1997; 120:1-13. (Pubitemid 27081256)
9. Rinaldi L, Gallo P, Calabrese M, Ranzato F, et al. Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI active patients. Brain 2006; 29: 1993-2007. (Pubitemid 44289065)
10. Ifergan I, Kébir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R, Arbour N, Prat A. The blood brain barrier induces differentiation of migrating monocytes into Th17 polarizing dendritic cells. Brain 2008; 131:785-799 (Pubitemid 351294709)
11. Del-Beato T, Berghella AM, Pellegrini P, Adorno D, Casciani CU. The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL 2 biotherapy. Cancer Biother Radiopharm 1997; 12: 297-304. (Pubitemid 28009373)
12. Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transplant Immunol 2003; 12:49-61.
13. Pellegrini P, Totaro R, Contasta I, Berghella AM, Carolei A, Adorno D. CD30 antigen and Multiple Sclerosis: CD30 an important costimulator molecule and marker for a regulatory subpopulation of dendritic cells involved in maintaining the physiological balance between TH1/TH2 immune response and tolerance; the role of IFNβ1a in reestablishing this regulation in Multiple Sclerosis. Neuroimmunomodulation 2005; 12:220-234 (Pubitemid 40910975)
14. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13:139-144 (Pubitemid 46245771)
15. Acerwenka A, Swain SL, TGF-β1: immunosuppressant and viability factor for T lymphocytes. Microbes Infect 1999; 15:1291-1296
16. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-238
17. Janes KA, Yaffe MB. Data driven modelling of signal transduction networks. Nat Rev 2006; 7:820-828
18. Li Y, Chu N, Rostami A, Zhang GX. Dendritic cells transduced with SOCS 3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J Immunol 2006; 177:1679-1688 (Pubitemid 44092504)
19. Kalinski P, Vieira PL, Schuitemake JK, De Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin 12p40 (IL12p40) production and an inhibitor of bioactive IL12p70 heterodimer. Blood 2001; 97:3466-3469
20. Banchereau J. Converging and diverging properties of human interleukin 4 and interleukin 10. Behring Institute Mitteilungen 1995; 96:58-77.
21. Cua DJ, Kastelein RA. TGFβ a 'double agent' in the immune pathology war. Nat Immunol 2006; 7:557-559
22. Pellegrini P, Totaro R, Contasta I, Berghella AM, Russo T, Carolei A, Adorno D. IFNbeta1a treatment and reestablishment of Th1 regulation in MS patients: dose effects. Neuropharmacol 2004; 27:258-269 (Pubitemid 40066227)
23. Bloemena E, Roos MT, Van-Heijst JL, Vossen JM, Schellekens PT. Whole blood lymphocyte cultures. J Immunol Methods 1989; 122:161-167
24. Bray D. Reasoning for results. Nature 2001; 412:863.
25. Janes KA, Lauffenburger DA. A biological approach to computational models of proteomic networks. Curr Opin Chem Biol 2006; 10:73-80. (Pubitemid 43202291)
26. Brennan FM, Green P, Amjadi P, Robertshaw HJ, Alvarez-Iglesias M, Takata M. Interleukin-10 regulates TNF-alpha-converting enzyme (TACE/ADAM-17) involving a TIMP-3 dependent and independent mechanism Eur J Immunol 2008; 38:1106-1117
27. Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, et al. IL 10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol 2008; 38:576-586
28. Blom B, Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006; 24:287-294
29. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168:5699-5708 (Pubitemid 34556153)
30. Shinomiya M, Fazle-Akbar SM, Shinomiya H, Onji M. Transfer of dendritic cells (DC) ex vivo stimulated with interferon gamma (IFN gamma) down modulates autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 1999; 117:38-43.
31. Kang MW, Jang JY, Choi JY, Kim SH, Oh J, Cho BS, Lee CE. Induction of IFN gamma gene expression by thioredoxin: positive feed back regulation of Th1 response by thioredoxin and IFN gamma. Cell Physiol Biochem 2008; 21:215-224
32. Endoh M, Kunishita T, Tabira T. Thioredoxin from activated macrophages as a trophic factor for central cholinergic neurons in vitro. Biochem Biophys Res Commun 1993; 192:760-765 (Pubitemid 23227387)
33. Nafar M, Farrokhi F, Vaezi M, Entezari AE, Pour-Reza-Gholi F, Firoozan A, Eniollahi B. Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection. Int Urol Nephrol 2009; 41:687-693
34. Polte T, Behrendt AK, Hansen G. Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol 2006; 118:942-948 (Pubitemid 44498761)
35. Yang SS, Fu LS, Chang CS, Yeh HZ, Chen GH, Kao JH. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21:1789-1793